The Filing Desk

Johnson & Johnson vs Moderna

Johnson & Johnson JNJ · Moderna MRNA · Health Care

Johnson & Johnson reported revenue of $94.2 billion in fiscal 2025, 48.5 times Moderna's $1.9 billion in fiscal 2025. Johnson & Johnson's revenue grew 6.0% in its latest year, and Moderna's fell 39.9%. Free cash flow was $19.7 billion at Johnson & Johnson and −$2.1 billion at Moderna. Their fiscal years end in different months (December 28 and December 31), so the periods don't line up exactly.

Side by side

Johnson & JohnsonModerna
Latest fiscal yearFY2025, Dec 28, 2025FY2025, Dec 31, 2025
Revenue$94.2B$1.9B
Revenue growth6.0%−39.9%
Revenue growth a year, last 5 years2.7%19.3%
Gross margin67.9%55.4%
Operating margin—−158.1%
Net margin28.5%−145.2%
Free cash flow$19.7B−$2.1B
Free cash flow margin20.9%−106.2%
Return on capital28.6%−65.4%
Net debt to EBITDA0.7x—
Dividends and buybacks$18.3B$2M
Change in diluted share count0.0%1.3%
Last close$267.14$199.33
P/E at the last close40.5×—
Insider trades, last 12 monthsbought $257,688, sold $154.4 millionsold $98.5 million
Piotroski F-score4 of 92 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Johnson & JohnsonModerna
Operating margin
Percent of revenue
Johnson & JohnsonModerna
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Johnson & JohnsonModerna

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Johnson & Johnson and Moderna pages.